Last updated: September 6, 2026
The guaifenesin and hydrocodone bitartrate market is a small, mature prescription cough-product segment with limited pricing power and declining structural demand. Guaifenesin is widely available over the counter, while hydrocodone bitartrate is a Schedule II opioid subject to prescribing controls, quota restrictions, abuse-deterrent policy, and state-level opioid regulation. The combination has no material biologic or formulation moat and is exposed to substitution by non-opioid cough medicines, standalone guaifenesin products, codeine products, and other prescription antitussives.
Public companies generally do not disclose revenue for hydrocodone-guaifenesin products separately. The commercial outlook is therefore best assessed through prescription volume, product availability, regulatory constraints, generic competition, and the declining role of opioid cough medicines in U.S. respiratory care.
What is the guaifenesin and hydrocodone bitartrate market?
Guaifenesin is an expectorant that loosens respiratory secretions. Hydrocodone bitartrate is an opioid antitussive and analgesic. Combination products are usually supplied as oral syrups or oral solutions.
The commercial product is primarily a U.S. prescription market. Guaifenesin alone has a broad consumer market through brands such as Mucinex and numerous store-brand products. Hydrocodone-guaifenesin combinations are narrower because the opioid component requires a prescription and carries Schedule II controls.
| Market characteristic |
Assessment |
| Primary dosage form |
Oral syrup or oral solution |
| Main therapeutic use |
Short-term cough suppression with expectorant activity |
| Prescription status |
Prescription-only because of hydrocodone |
| Controlled-substance status |
U.S. Schedule II |
| Major demand driver |
Acute cough treatment and selected respiratory conditions |
| Main substitutes |
Guaifenesin alone, dextromethorphan, benzonatate, codeine combinations, hydrocodone-homatropine products |
| Patent profile |
Mature and generally weak |
| Biosimilar exposure |
None |
| Revenue disclosure |
Usually not reported separately |
| Commercial risk |
Opioid controls, declining opioid prescribing, supply restrictions, and generic substitution |
How large is the financial opportunity for hydrocodone-guaifenesin products?
The combination is unlikely to be a material revenue contributor for diversified pharmaceutical companies. Its value is concentrated in product portfolios that include controlled-substance liquids, generic prescription medicines, or specialty distribution businesses.
Financial performance is shaped by prescription volume rather than population growth. U.S. opioid prescribing has declined substantially from its 2011 peak, although opioid dispensing remains significant in some therapeutic categories. CDC data show a long-term reduction in opioid prescribing rates, with further pressure from prescribing guidelines, payer controls, state limits, and pharmacy scrutiny (Centers for Disease Control and Prevention, 2024).
Revenue trajectory
The financial trajectory has four phases:
| Period |
Commercial condition |
Financial effect |
| Pre-2010 |
More permissive opioid prescribing and broader cough-product use |
Higher prescription potential |
| 2010-2016 |
Rising opioid scrutiny and new prescribing controls |
Volume pressure begins |
| 2017-2020 |
Federal opioid policy, state limits, and pharmacy restrictions |
Persistent demand contraction |
| 2021 onward |
Mature, low-growth prescription segment with supply volatility |
Stable-to-declining base business |
Manufacturers may obtain temporary price increases when competitors experience shortages or exit the market. Those gains are vulnerable because the underlying product is generally substitutable and lacks strong intellectual-property protection.
A product-level revenue forecast is not supportable from public filings because manufacturers typically aggregate cough products within broader generic, specialty, or prescription portfolios. The appropriate commercial conclusion is that hydrocodone-guaifenesin products are niche revenue assets, not growth platforms.
What is the FDA regulatory status of hydrocodone and guaifenesin combinations?
Hydrocodone-guaifenesin oral solutions have been marketed as prescription products under FDA-approved product labeling and, in some cases, under abbreviated applications or legacy regulatory pathways. Product status must be evaluated by the specific manufacturer, application number, National Drug Code, and formulation.
Hydrocodone is subject to strict FDA and Drug Enforcement Administration requirements. Since 2014, hydrocodone combination products have been classified as Schedule II controlled substances, which removed the refill flexibility available to Schedule III products and increased prescribing and dispensing controls (Drug Enforcement Administration, 2014).
The regulatory burden includes:
- Schedule II prescription requirements.
- No refills under federal controlled-substance rules.
- Manufacturing quotas for hydrocodone.
- Controlled-substance recordkeeping.
- Increased pharmacy and wholesaler monitoring.
- State opioid-prescribing restrictions.
- FDA scrutiny of pediatric cough-and-cold use.
- Risk-management obligations related to misuse, abuse, addiction, overdose, and diversion.
The FDA has warned against using prescription opioid cough medicines in children younger than 18 because of the risk of misuse, respiratory depression, overdose, and death. Pediatric labeling restrictions reduce the addressable market for opioid cough products (U.S. Food and Drug Administration, 2018).
What patents protect guaifenesin and hydrocodone bitartrate products?
The active ingredients do not provide a meaningful current patent barrier.
Guaifenesin has been marketed for decades and is available in numerous over-the-counter products. Hydrocodone bitartrate is also an established active ingredient. Any historical composition-of-matter protection for these ingredients has expired.
Potential intellectual-property rights may cover:
- Specific liquid formulations.
- Taste-masking systems.
- Preservative combinations.
- Extended-release delivery.
- Abuse-deterrent technologies.
- Manufacturing processes.
- Container-closure systems.
- Specific methods of treating cough.
These rights generally have narrower commercial scope than active-ingredient patents. A formulation patent can be designed around if a competitor uses different excipients, concentrations, manufacturing steps, or packaging.
Patent-strength assessment
| Patent category |
Strength for standard immediate-release product |
| Active ingredient patent |
None of practical significance |
| Basic combination patent |
Weak or expired |
| Standard syrup formulation |
Weak |
| Taste masking |
Moderate only if technically difficult to design around |
| Abuse deterrence |
Potentially stronger, but product-specific |
| Manufacturing process |
Usually narrow |
| Method of use |
Limited commercial leverage |
| Trade secret |
Possible for process and formulation know-how |
| Regulatory exclusivity |
Generally limited for mature products |
The strongest defensible position would require a technically differentiated formulation, such as an abuse-deterrent liquid or a proprietary extended-release delivery system. Standard immediate-release hydrocodone-guaifenesin syrup generally has limited patent protection.
What is the Orange Book status of hydrocodone-guaifenesin products?
Orange Book analysis must be performed at the product level. The relevant questions are whether the specific approved product has listed patents, whether those patents carry pediatric or method-of-use indications, and whether an ANDA applicant has made a Paragraph IV certification.
For a mature hydrocodone-guaifenesin oral solution, the commercial expectation is limited Orange Book protection unless the sponsor has listed a surviving formulation, delivery, or use patent. A product may remain commercially available without having a meaningful patent estate.
The absence of a strong listed patent position changes the competitive process. Generic applicants can rely on bioequivalence and pharmaceutical-equivalence requirements rather than developing a novel active ingredient. If an applicant makes a Paragraph IV certification against a listed patent, litigation may follow under the Hatch-Waxman framework. If no relevant patent is listed, the main barriers are FDA approval, controlled-substance manufacturing capacity, and market economics.
When does hydrocodone-guaifenesin lose exclusivity?
There is no single universal loss-of-exclusivity date for the combination. Exclusivity depends on the specific FDA application and product.
Relevant exclusivity categories include:
| Exclusivity type |
Typical relevance |
| New chemical entity exclusivity |
Not expected for these established ingredients |
| New clinical investigation exclusivity |
Possible only for qualifying new studies |
| Orphan exclusivity |
Not generally relevant |
| Pediatric exclusivity |
Product-specific and temporary |
| Three-year exclusivity |
Possible for qualifying new formulation or indication approvals |
| Patent exclusivity |
Depends on listed formulation, use, or delivery patents |
| Market protection from supply constraints |
Temporary and nonexclusive |
Any original active-ingredient exclusivity has expired. Commercial exclusivity therefore depends mainly on application-specific formulation rights, regulatory history, product availability, and the number of approved competitors.
How many generic competitors challenge hydrocodone-guaifenesin products?
The number of effective competitors is usually lower than the number of approved or listed NDCs. Many NDCs belong to different package sizes, distributors, repackagers, or manufacturers using the same underlying supply source.
Competition is constrained by:
- Limited demand.
- Schedule II manufacturing quotas.
- Controlled-substance compliance costs.
- Low expected return on new ANDA development.
- Limited pharmacy inventory.
- Product discontinuations.
- Difficulty forecasting acute cough demand.
- Liability and reputational risk associated with opioid products.
The market can therefore display a paradox: weak patent protection but limited practical competition. A generic may be legally able to enter yet commercially unwilling to invest in manufacturing, inventory, regulatory compliance, and distribution.
What generic entry risks exist?
Generic entry risk is high from a legal perspective but moderate from a commercial-volume perspective.
A competitor can potentially enter through an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence to the reference product. The core risks to an incumbent are:
- Price erosion from additional approved suppliers.
- Formulary substitution.
- Loss of preferred wholesaler access.
- Retail pharmacy substitution.
- Repackager competition.
- Increased supply volatility if manufacturers exit after price compression.
The incumbent’s countervailing advantage is operational. Controlled-substance manufacturing, quota allocation, compliance systems, and reliable distribution can create practical barriers that patents do not provide.
Which companies compete in the hydrocodone cough market?
Competition includes branded manufacturers, specialty pharmaceutical companies, generic drugmakers, and contract manufacturers. The competitive set changes because products are discontinued, transferred, relabeled, or temporarily unavailable.
Relevant competitor categories include:
- Manufacturers of hydrocodone-guaifenesin oral solutions.
- Producers of hydrocodone-homatropine products.
- Companies selling codeine-based cough products.
- Producers of benzonatate.
- Manufacturers of dextromethorphan and guaifenesin products.
- OTC respiratory-care companies.
- Contract manufacturers with controlled-substance capabilities.
Guaifenesin-only products have the broadest competitive base. Hydrocodone-containing products compete in a narrower prescription channel and face stronger regulatory friction.
What litigation and settlement risks affect the market?
Patent litigation risk is generally limited unless a sponsor has listed a surviving formulation or delivery patent. The more significant legal risks arise from opioid marketing, controlled-substance distribution, product liability, false claims, and failure to maintain adequate compliance systems.
Potential disputes include:
- Hatch-Waxman litigation after a Paragraph IV certification.
- Patent infringement claims involving a liquid formulation.
- Product-liability claims involving respiratory depression or overdose.
- Government investigations involving controlled-substance distribution.
- False Claims Act allegations tied to promotion or reimbursement.
- Contract disputes involving manufacturing or supply allocation.
Publicly announced settlement agreements are product-specific and cannot be inferred from the active ingredients alone. A settlement that delays generic entry would matter only if the reference product had a surviving enforceable patent and meaningful prescription demand.
What manufacturing and supply barriers protect the market?
Manufacturing capability is more important than formulation know-how for many hydrocodone-guaifenesin products.
Key barriers include:
- DEA registration and quota allocation.
- Secure handling of Schedule II materials.
- Batch-release testing.
- Controlled-substance inventory reconciliation.
- Tamper-resistant packaging and serialization requirements.
- Reliable supply of hydrocodone active pharmaceutical ingredient.
- Specialized liquid-filling capacity.
- Stability and preservative control.
- Distribution through compliant wholesalers and pharmacies.
Supply disruptions can temporarily improve pricing for an incumbent with available inventory. The effect is usually short-lived because buyers can substitute among cough medicines, reduce prescribing, or switch to non-opioid products.
How does hydrocodone-guaifenesin compare with competing cough medicines?
| Product category |
Prescription status |
Opioid exposure |
Market breadth |
Patent strength |
| Hydrocodone-guaifenesin |
Prescription |
High |
Narrow |
Low |
| Hydrocodone-homatropine |
Prescription |
High |
Narrow |
Low |
| Codeine cough products |
Prescription |
High |
Narrow to moderate |
Low |
| Benzonatate |
Prescription |
None, but poisoning risk |
Moderate |
Mature |
| Dextromethorphan |
OTC |
None at therapeutic use |
Broad |
Low |
| Guaifenesin alone |
OTC |
None |
Very broad |
Low |
| Extended-release guaifenesin |
OTC |
None |
Broad |
Low to moderate by formulation |
The combination’s clinical differentiation is limited. Guaifenesin provides expectorant activity, while hydrocodone suppresses cough. The same therapeutic objectives can often be addressed with non-opioid products, especially when prescribers and patients prioritize safety, access, and lower regulatory friction.
What is the long-term commercial outlook?
The base case is a declining or flat prescription market with intermittent price expansion caused by shortages. Volume is likely to remain constrained by opioid policy, age-specific restrictions, payer scrutiny, and substitution toward non-opioid therapies.
The product can remain commercially viable when a supplier has:
- A dependable controlled-substance manufacturing platform.
- Low-cost production.
- Reliable wholesaler access.
- A recognized prescription portfolio.
- Temporary supply scarcity among competitors.
- A differentiated formulation that reduces substitution.
The product is less attractive as a standalone development project. Development economics are weakened by low market growth, limited patent protection, controlled-substance compliance, and the availability of inexpensive alternatives.
Key Takeaways
- Hydrocodone-guaifenesin is a mature, niche prescription cough market.
- Guaifenesin contributes broad therapeutic familiarity but little exclusivity.
- Hydrocodone creates regulatory burden, not durable patent protection.
- Active-ingredient patents and original exclusivities have expired.
- Product-level Orange Book and Paragraph IV analysis is required because protection depends on the specific application.
- Revenue is rarely disclosed separately and is unlikely to be material for diversified manufacturers.
- Generic legal entry risk is high, but controlled-substance manufacturing and limited demand reduce the number of effective competitors.
- The strongest commercial assets are supply reliability, compliance infrastructure, and distribution rather than patents.
- Long-term volume is pressured by opioid restrictions and substitution toward non-opioid cough medicines.
- Biosimilar risk is not relevant because the product is a small-molecule drug, not a biologic.
FAQs
Is hydrocodone-guaifenesin an opioid product?
Yes. Hydrocodone bitartrate is an opioid and is classified as a Schedule II controlled substance in the United States.
Is guaifenesin protected by active-ingredient patents?
No meaningful active-ingredient patent protection remains for standard guaifenesin products. Current protection, where present, would relate to formulation, delivery, packaging, or manufacturing.
Can a generic company make hydrocodone-guaifenesin syrup?
Yes, subject to FDA approval, bioequivalence requirements, controlled-substance registration, DEA quota, manufacturing compliance, and distribution controls.
Are hydrocodone-guaifenesin products eligible for biosimilar competition?
No. Biosimilar regulation applies to biologic products. Hydrocodone-guaifenesin is a small-molecule drug and competes through generic-drug pathways.
What is the largest commercial threat to hydrocodone-guaifenesin products?
The largest structural threat is substitution toward non-opioid cough medicines, especially guaifenesin, dextromethorphan, benzonatate, and other products that avoid Schedule II restrictions.
References
-
Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps, 2010-2022. U.S. Department of Health and Human Services.
-
Drug Enforcement Administration. (2014). Schedules of controlled substances: Rescheduling of hydrocodone combination products from Schedule III to Schedule II. Federal Register, 79 Fed. Reg. 49661.
-
U.S. Food and Drug Administration. (2018). FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
